A great post from MarkDayCEO1 over on Stockhouse.

"Hi everyone, as you know we have formed a superb SAB with some of the best CNS experts across academia and pharma. The role of the SAB is to pressure test our science and advise on the best next steps in the scientific process, leading to publication, etc. Please note that new data can help lock down and strengthen intellectual property. Also, new data, when released in isolation, can be misleading or misinterpreted. For example, imagine MedImmune released only their control antibody study - it would have caused speculation, often erroneous misinterpretation and would damage IP protection. You all saw how the manuscript told a compelling story as several data points, presented together, told a solid story. So be assured we are working on studies that tell a complete study, not single data points. We should all be proud of the additions that have come to Bioasis. We need to let the scientific process take place. This is not a company of isolated news releases, this is a company with big, but realistic ambitions, that is significantly undervalued and has a great shareholder base. You will notice that our press releases tell a story of advancement. We have all the ingredients to make an impact. We are on it and will act in the best long-term of our shareholders. Very best, Bioasis"